Clinical effectiveness of very low energy diets in the management of weight loss

Parretti, Helen; Jebb, Susan; Johns, David ; Lewis, Amanda ; Christian-Brown, Anna ; Aveyard, Paul

DOI:
10.1111/obr.12366

Document Version
Peer reviewed version

Citation for published version (Harvard):
Parretti, H, Jebb, S, Johns, D, Lewis, A, Christian-Brown, A & Aveyard, P 2016, 'Clinical effectiveness of very low energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials', *Obesity Reviews*. https://doi.org/10.1111/obr.12366

Clinical effectiveness of very low energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials

HM Parretti, PhD[1], SA Jebb, PhD[2], DJ Johns, PhD[3] AL Lewis, PhD[4], AM Christian-Brown, MSc[2] and P Aveyard, PhD[2]

1. Primary Care Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
2. Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road Oxford, OX2 6GG, UK
3. Human Nutrition Research, Medical Research Council, UK and Public Health Derby Teaching Hospitals NHS Foundation Trust, UK
4. School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS

Appendices

Sample search strategy (Medline)

1. Very low calorie diet.ab,hw,kw,ot,sh,ti.
2. Very low energy diet.ab,hw,kw,ot,sh,ti.
3. Vlcd.ab,hw,kw,ot,sh,ti.
4. Vled.ab,hw,kw,ot,sh,ti.
5. Very-low-calorie.ab,hw,kw,ot,sh,ti.
6. Very-low-energy.ab,hw,kw,ot,sh,ti.
7. Very low calorie.ab,hw,kw,ot,sh,ti.
8. Very low energy.ab,hw,kw,ot,sh,ti.
9. Very-low-calorie diet.ab,hw,kw,ot,sh,ti.
10. Very-low-energy diet.ab,hw,kw,ot,sh,ti.
11. Cambridge diet.ab,hw,kw,ot,sh,ti.
12. Lighterlife.ab,hw,kw,ot,sh,ti.
13. Diet.ab,hw,kw,ot,sh,ti.
14. Diets.ab,hw,kw,ot,sh,ti.
15. "Obes*".ab,hw,kw,ot,sh,ti.
16. Overweight.ab,hw,kw,ot,sh,ti.
17. Weight loss.ab,hw,kw,ot,sh,ti.
18. Dieting.ab,hw,kw,ot,sh,ti.
19. "Lighter life".ab,hw,kw,ot,sh,ti.
20. weight change.ab,hw,kw,ot,sh,ti.
21. 13 or 14 or 15 or 16 or 17 or 18 or 20
22. nutrilett.ab,hw,kw,ot,sh,ti.
23. modifast.ab. or modifast.ot. or modifast.sh. or modifast.ti.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 19 or 22 or 23
25. 21 and 24

Supplementary tables and figures

Table S1: Excluded full papers

Paper	Grounds for exclusion
Lantz 2003 (1)	Intermittent VLED
Ryttig 1995 (2)	Intermittent VLED
Wing 1984 (3)	Intermittent VLED
Viegener 1990 (4)	Intermittent VLED
Torgerson 1999 (5)	VLED in comparator arm
Wadden 1985 (6)	VLED in comparator arm
Snel 2011 (7)	VLED in comparator arm
Snel 2012 (8)	VLED in comparator arm
Pavlou 1989 (9)	VLED in comparator arm
Rossner 1998 (10)	VLED in comparator arm
Dixon 2012 (11)	Surgical comparator
Andersen 1987 (12)	Surgical comparator
Gripeteg 2010 (13)	Weight maintenance
Lecheminant 2005 (14)	Weight maintenance
Wikstrand 2010 (15)	Non-randomized study
Murray 2010 (16)	Non-randomized study
Christensen 2010 (17)	Non-randomized study
Richelsen 2007 (18)	Non-randomized study
Mathus-Vliegen 2005 (19)	Non-randomized study
Kajaste 2004 (20)	Non-randomized study
Zahouani 2003 (21)	Non-randomized study
Kaukua 2003 (22)	Non-randomized study
Melin 2003 (23)	Non-randomized study
Paisey 1998 (24)	Non-randomized study
Andersen 1992 (25)	Non-randomized study
Apfelbaum 1999 (26)	Non-randomized study
Paisey 2002 (27)	Non-randomized study
Wadden 1997 (28)	Non-randomized study
Capstick 1997 (29)	Non-randomized study
Agras 1996 (30)	Non-randomized study
Kamrath 1992 (31)	Non-randomized study
Sikand 1988 (32)	Non-randomized study
Finer 1989 (33)	Non-randomized study
Shovic 1993 (34)	Non-randomized study
Miura 1989 (35)	Non-randomized study
Anderson 2001 (36)	Review article
Tsai 2006 (37)	Review article
Kreitzman 1989 (38)	Review article
Lin 2009 (39)	Follow-up less than 12 months
Kaukua 2002 (40)	Follow-up less than 12 months
Arai 1992 (41)	Follow-up less than 12 months
Foster 1990 (42)	Follow-up less than 12 months
Foster 1992 (43)	Follow-up less than 12 months
Inoue 1989 (44)	Follow-up less than 12 months
Toubro 1997 (45)	Authors unable to provide data requested
Simonen 2000 (46)	Authors unable to provide data requested
Wadden 1989 (47)	Authors unable to provide data requested
Rolland trial protocol 2011 (48)	Authors unable to provide data requested
Bliddal 2011 (49)	VLED contained more than 800kcal/day

Table S2: Summary of study characteristics

Study ID	Location	Population	Intervention	Comparator	Outcomes reported during study	Follow Up and % completers
Pekkarinen 1997 (50)	Finland	N=59, morbidly obese, 57.8% F	Dietta Mini, liquid meal and vegetables for 6-8 weeks, 500Kcal/day Low energy food from 14 weeks Behavioural therapy for 16 weeks	Behavioural therapy for 16 weeks	Weight change, 5% weight loss, 10% weight loss, 20% weight loss, SCL-90 GSI scores, dietary adherence, adverse effects	4, 60 months. Completers: 44% comparator, 50% intervention at 60 months.
Purcell 2014 (51)	Australia	N=200, obese, 74.5% F	Optifast meal replacements, 450-800kcal/day for 12 weeks (replacing meals) then individualised diet for weight maintenance, if regain changed to 400-500kcal/day deficit diet up to 144 weeks. Behavioural therapy every 2 weeks (6 sessions) and then every 12 weeks for 144 weeks.	400-500kcal/day deficit diet for 36 weeks with 1 or 2 meals replaced by Optifast a day. Then maintenance as intervention up to 144 weeks. Behavioural therapy every 2 weeks (18 sessions) and then every 12 weeks for 144 weeks.	Weight change, fasting gherlin and leptin levels, subjective appetite, change in physical activity levels, fat mass, fat free mass, hip circumference and waist circumference 3-β-hydroxybutyrate levels, adverse events	12 weeks-rapid group, 36 weeks-gradual group), 144 weeks -both groups, (data from authors at 48 and 108 weeks). Completers: 44% comparator, 64% intervention at 48 weeks. Completers: 28% comparator, 52% intervention at 108 weeks.
Rolland 2009 & 2010 (52, 53)	UK	N=72, obese, 84% F	600kcal/day deficit diet and lifestyle advice for 9 months initially and failed to lose >5% body weight Lighterlife, food replacements for 3-9 months, 550Kcal/day Behavioural therapy with weekly group sessions Constant support via email and telephone	600kcal/day deficit diet and lifestyle advice for 9 months initially and failed to lose >5% body weight Low calorie high protein (800-1500 kcal/day, ≤40g carbohydrate/ day) Constant support via email and telephone	Weight change, body composition, waist circumference, BP, lipids, electrolytes, eGFR, fasting glucose, fasting insulin, HbA1c, bilirubin, albumin	3, 9 and 24 months. Completers: 26% comparator, 29% intervention at 24 months.

Rossner 1997 (54)	Norway	N=93, obese, 68% F	Nutrilett, food substitutes for 6 weeks Booster for 2 weeks at 27 weeks 1) 420Kcal/day 2) 530Kcal/day HCD between VLED and after VLED up to 52 weeks. Behavioural support sessions, from 26-52 weeks	LCD (880kcal/day) for 6 weeks Booster for 2 weeks at 27 weeks HCD between LCD and after LCD up to 52 weeks. Behavioural support sessions, as per intervention arm	Weight change, % body fat, waist circumference, hip circumference, WHR, sagittal diameter, ECG, BP*, lipids*, glucose*, adverse effects	1,6 and 12 months. Completers: 55% comparator, 70% intervention 420kcal, 59% intervention 530kcal at 12 months.
Ryttig 1997 (55)	Sweden	N=81, obese, 54.3% F	Nutrilett, liquid, for 2 months, 420Kcal/day 1 week transition then balanced deficit diet to 1600kcal/ day for 26 months Behavioural therapy for 26 months (weekly for first month, then every fortnight for second month, monthly for months 3-9 and every 7 weeks for months 10-26)	Balanced deficit diet with 1600kcal/day for 26 months Behavioural therapy for 26 months as intervention	Weight change, % body fat loss, wasit circumference, BP, HR, ECG, electrolytes, glucose, cholesterol, urine ketone body, adverse effects	2, 8, 12 and 24 months. Completers: 78% comparator, 74% intervention at 12 months. Completers: 59% comparator, 48% intervention at 24 months.
Stenius 2000 (56)	Finland	N=38, obese, asthma, 76.3% F	Nutrilett, liquid for 8 weeks, 420Kcal/day Transition period over 8 weeks and then 500-1000 kcal/ day deficit diet Behavioural therapy group weekly for 12 weeks	Behavioural therapy group weekly for 12 weeks	Weight change, PEF**, FVC, FEV1, QoL (SGRQ), asthma symptoms, acute episodes and use of oral steroids	3 and 12 months. Completers: 100% comparator, 100% intervention at 12 months.
Torgerson 1997 & Lantz 2003 (57, 58)	Sweden	N=113, obese, 65.5% F	Modifast, liquid for 12 weeks, 456-608Kcal/day 1200-1400kcal/ day (female) or 1400-1800kcal/ day (male) diet for 21 months Behavioural therapy 59 sessions over 4 years	1200-1400kcal/day (female) or 1400-1800kcal/day (male) diet for 21 months Behavioural therapy 56 sessions over 4 years	Weight change, 5% weight loss, 10% weight loss, adverse effects	3, 6, 12, 18, 24 and 48 months. Completers: 91% comparator, 88% intervention at 12 months. Completers: 47% comparator,

						50% intervention at 48 months.
Tuomilehto 2009 & 2010 (59, 60)	Finland	N=81, overweight, mild OSA, 26.35% F	Modifast, Natrifast or Naturdiet for 12 weeks, 600-800Kcal/day Followed by fat restriction diet (no more than 30% total energy) Behavioural support 14 sessions over 12 months (6 during VLED phase)	Brief intervention on diet and exercise given at baseline, 3 and 12 months.	Weight change, waist circumference, HR, lipids, BP, fasting glucose, fasting insulin, oxygen saturation, AHI**, ESS, SOS, QoL, number of witnessed apnoea, adverse effects	3, 12 and 24 months. Completers: 90% comparator, 88% intervention at 12 months. Completers: 88% comparator, 88% intervention at 24 months.
Wadden 1986 & 1988 (61, 62)	USA	N=59, overweight (obese in 1988), 84.7% F	Preceded by 1000-1200kcal/ day diet for 4 wks PSMF for 8 weeks, 400-500Kcal/day Followed by refeeding period for 4 weeks and 8 weeks 1000-1200kcal/ day diet 1) VLED only as above 2) VLED as above and behavioural therapy over 12 months (11 sessions)	1000-1200kcal/day diet for 6 months and behavioural therapy over 12 months (11 sessions)	Weight change, BDI	6, 12 and 42 months. Completers: 89% comparator, 83% intervention (VLED alone), 74% intervention (VLED+BT) at 12 months. Completers: 83% comparator, 72% intervention (VLED alone), 74% intervention (VLED+BT) at 42 months.
Wadden 1994 (63)	USA	N=49, obese, 100% F	Preceded by 1200kcal/ day diet for 1 week Optifast, liquid for 16 wks, 420Kcal/day Transition period for 5 weeks, followed by 28 weeks 1200kcal/ day diet and then 26 weeks of weight maintenance diet	1200kcal/day diet Behavioural therapy as per intervention arm	Weight change, body composition, % lost 5kg, % lost 10kg, % lost 20kg, BDI, BES	1, 2, 4, 6, 12 and 18 months. Completers: 81% comparator, 82% intervention at 12 months.

			Behavioural therapy weekly for 12 months and then biweekly for 6 months			
Wing 1991 (64)	USA	N=36, obese, T2DM, 75.5% F	Preceded by 1000-1505 kcal/day diet for 4 weeks Optifast, liquid or lean meat for 8 weeks, 400Kcal/day Transition period for 8 weeks and then maintenance diet (1000-1505kcal/day) until week 72 Behavioural therapy, 24 sessions	1000-1505kcal/day diet for 20 weeks minimum Remain on calorie deficit until target weight reached and then maintenance programme Behavioural therapy as per intervention arm	Weight change, HbA1c, lipids, fasting insulin, fasting glucose, insulin:glucose ratio, PAQ, EBI, adverse effects	5 and 17 months. Completers: 84% comparator, 100% intervention at 17 months.
Wing 1994-1996 (65-67)	USA	N=93, obese, T2DM , 65% F	Optifast, liquid or lean meat for 12 weeks, 400-500Kcal/day, second 12 week phase of VLED after 24 weeks 1000-1200kcal/day diet for 12 weeks between VLED phases and after second VLED phase Behavioural therapy weekly for 50 sessions	1000-1200kcal/day diet Behavioural therapy weekly for 50 sessions	Weight change, HbA1c, lipids, fasting glucose, fasting insulin, BP, BDI, adverse effects	3, 12 and 24 months. Completers: 85% comparator, 84% intervention at 12 months. Completers: 77% comparator, 80% intervention at 24 months.

* At baseline and 6 months only
** Primary outcome
SGRQ – St George's Respiratory Questionnaire, PEF – Peak Expiratory Flow, FVC – Forced Vital Capacity, FEV1 – Forced Expiratory Volume in 1 minute, BDI – Beck Depression Index, ESS – Epworth Sleepiness Scale, SOS – Snore Outcome Survey, AHI – Apnoea Hyponea Index, PAQ – Paffenberger Activity Questionnaire, EBI – Eating Behaviour Inventory, BES – Binge Eating Scale, WHR – Waist Hip Ratio

Table S3: Risk of bias assessment

Study ID	Sequence generation	Allocation concealment	Attrition	Selective reporting
Pekkarinen 1997	High	High	Low	Low
Purcell 2014	Low	Low	Low	Low
Ryttig 1997	Unclear	Unclear	Unclear	Low
Wadden 1994	Unclear	Unclear	Low	Low
Wing 1991	Unclear	Unclear	Low	Low
Wing 1994	Unclear	Unclear	Low	Low
Stenius 2000	Unclear	Low	Low	Low
Wadden 1986 and 1988	Unclear	Low	Low	Low
Tuomilheto 2009 and 2010	Low	Low	Low	High
Rolland 2009 and 2010	Unclear	Unclear	Low	Low
Torgerson 1997 and Lantz 2003	Unclear	Low	Low	Unclear
Rossner 1997	Unclear	Unclear	Low	Low

Note that blinding is not reported as it is not possible to blind therapists or participants. Incomplete outcome data are not assessed either because we have addressed this in recalculating the outcomes.

Figure S1: Forest plot weight change at 12 months, complete data



Figure S2: Forest plot BOCF weight change at 12 months, subgroups on participant group



Figure S3: Forest plot BOCF weight change at 12 months, subgroups on formulation of VLED



Figure S4: Forest plot BOCF weight change at 12 months, subgroups on single or multiple VLED phase



Figure S5: Forest plot BOCF weight change at 24 months



Figure S6: Forest plot BOCF weight change at 38-60 months



Figure S7: Forest plot fasting glucose at 12 months (BOCF)



Figure S8: Forest plot HbA1c at 12 months (BOCF)



Figure S9: Forest plot fasting insulin at 12 months (BOCF)



Figure S10: Forest plot HDL at 12 months (BOCF)



Figure S11: Forest plot LDL at 12 months (BOCF)



Figure S12: Forest plot systolic BP at 12 months (BOCF)



Figure S13: Forest plot diastolic BP at 12 months (BOCF)



Figure S14: Forest plot BDI at 12 months (BOCF)



References

1. Lantz H, Peltonen M, Agren L, Torgerson JS. Intermittent versus on-demand use of a very low calorie diet: a randomized 2-year clinical trial. J Intern Med. 2003;253(4):463-71.
2. Ryttig KR, Rossner S. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. A prospective, randomized, comparative, controlled long-term trial. J Intern Med. 1995;238(4):299-306.
3. Wing RR, Epstein LH, Marcus MD, Koeske R. Intermittent low-calorie regimen and booster sessions in the treatment of obesity. Behavioural Research Therapy. 1984;22(4):445-9.
4. Viegener BJ, Perri MG, Nezu AM, Renjillian DA, McKelvey WF, Schein RL. Effects of an Intermittent, Low-Far, Low-Calorie Diet in the Behavioural Treatment of Obesity. Behaviour Therapy. 1990;21:499-509.
5. Torgerson J, Agren L, Sjostrom L. Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. International Journal of Obesity. 1999;23(2):190-7.
6. Wadden TA, Stunkard AJ, Brownell KD, Day SC. A comparison of two very-low-calorie diets: protein-sparing-modified fast versus protein-formula-liquid diet. American Journal of Clinical Nutrition. 1985;41(3):533-9.
7. Snel M, van Diepen JA, Stijnen T, et al. Immediate and long-term effects of addition of exercise to a 16-week very low calorie diet on low-grade inflammation in obese, insulin-dependent type 2 diabetic patients. Food and Chemical Toxicology. 2011;49(12):3104-11.
8. Snel M, Sleddering MA, Vd Peijl ID, et al. Quality of life in type 2 diabetes mellitus after a very low calorie diet and exercise. European Journal of Internal Medicine. 2012;23(2):143-9.
9. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;49:1115-23.
10. Rossner S. Intermittent vs continuous VLCD therapy in obesity treatment. International Journal of Obesity. 1998;22(2):190-2.
11. Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. Jama. 2012;308(11):1142-9.
12. Andersen T, Stokholm KH, Nielsen PE. Blood pressure and arm circumference during large weight reduction in normotensive and borderline hypertensive obese patients. J Clin Hypertens. 1987;3(4):547-53.
13. Gripeteg L, Torgerson J, Karlsson J, Lindroos AK. Prolonged refeeding improves weight maintenance after weight loss with very-low-energy diets. British Journal of Nutrition. 2010;103(1):141-8.
14. LeCheminant JD, Jacobsen DJ, Hall MA, Donnelly JE. A comparison of meal replacements and medication in weight maintenance after weight loss. J Am Coll Nutr. 2005;24(5):347-53.
15. Wikstrand I, Torgerson J, Bostrom KB. Very low calorie diet (VLCD) followed by a randomized trial of corset treatment for obesity in primary care. Scand J Prim Health Care. 2010;28(2):89-94.
16. Murray S, Sniehotta FF, Broom J, Araujo-Soares V. Positive and active weight loss study: A protocol for a goal-setting, planning and self-monitoring (GPS) intervention to increase walking in an obese sample. Obesity Reviews. 2010;11:322.
17. Christensen R, Leeds AR, Lohmander S, et al. Efficacy of dieting or exercise versus control in obese osteoarthritis patients after a clinically significant weight loss: A pragmatic randomized controlled trial. Obesity Reviews. 2010;11:248.
18. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: A 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30(1):27-32.
19. Mathus-Vliegen EM, Balance Study G. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind,

placebo-controlled, parallel group study. European Journal of Clinical Nutrition. 2005;59 Suppl 1:S31-8; discussion S9.
20. Kajaste S, Brander PE, Telakivi T, Partinen M, Mustajoki P. A cognitive-behavioral weight reduction program in the treatment of obstructive sleep apnea syndrome with or without initial nasal CPAP: a randomized study. Sleep Med. 2004;5(2):125-31.
21. Zahouani A, Boulier A, Hespel JP. Short- and long-term evolution of body composition in 1389 obese outpatients following a very low calorie diet (Pro'gram18 VLCD). Acta Diabetol. 2003;40 Suppl 1:S149-50.
22. Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification--a 2-y follow-up study. Int J Obes Relat Metab Disord. 2003;27(10):1233-41.
23. Melin I, Karlstrom B, Lappalainen R, Berglund L, Mohsen R, Vessby B. A programme of behaviour modification and nutrition counselling in the treatment of obesity: a randomised 2-y clinical trial. Int J Obes Relat Metab Disord. 2003;27(9):1127-35.
24. Paisey RB, Harvey P, Rice S, et al. An intensive weight loss programme in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year. Diabet Med. 1998;15(1):73-9.
25. Anderson JW, Brinkman VL, Hamilton CC. Weight loss and 2-y follow-up for 80 morbidly obese patients treated with intensive very-low-calorie diet and an education program. American Journal of Clinical Nutrition. 1992;56(1 SUPPL.):244S-6S.
26. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106(2):179-84.
27. Paisey RB, Frost J, Harvey P, et al. Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes. J Hum Nutr Diet. 2002;15(2):121-7.
28. Wadden TA, Frey DL. A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up. Int J Eat Disord. 1997;22(2):203-12.
29. Capstick F, Brooks BA, Burns CM, Zilkens RR, Steinbeck KS, Yue DK. Very low calorie diet (VLCD): a useful alternative in the treatment of the obese NIDDM patient. Diabetes Res Clin Pract. 1997;36(2):105-11.
30. Agras WS, Berkowitz RI, Arnow BA, et al. Maintenance following a very-low-calorie diet. Journal of Consulting and Clinical Psychology. 1996;64(3):610-3.
31. Kamrath RO, Diner RG, Plummer LJ, Sadur CN, Weinstein RL. Repeated use of the very-low-calorie diet in a structured multidisciplinary weight-management program. American Journal of Clinical Nutrition. 1992;56(1 Suppl):288S-9S.
32. Sikand G, Kondo A, Foreyt JP, Jones PH, Gotto AM, Jr. Two-year follow-up of patients treated with a very-low-calorie diet and exercise training. Journal of the American Dietetic Association. 1988;88(4):487-8.
33. Finer N, Finer S, Naoumova RP. Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine. International Journal of Obesity. 1989;13 Suppl 2:91-3.
34. Shovic AC, Adams S, Dubitzky J, Anacker M. Effectiveness and dropout rate of a very-low-calorie diet program. Journal of the American Dietetic Association. 1993;93(5):583-4.
35. Miura J, Arai K, Tsukahara S, Ohno M, Ikeda Y. The long term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 years follow-up. International Journal of Obesity. 1989;13 Suppl 2:73-7.
36. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. American Journal of Clinical Nutrition. 2001;74(5):579-84.
37. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity. 2006;14(8):1283-93.

38. Kreitzman SN. Lean body mass, exercise and VLCD. International Journal of Obesity. 1989;13(SUPPL. 2):17-25.
39. Lin WY, Wu CH, Chu NF, Chang CJ. Efficacy and safety of very-low-calorie diet in Taiwanese: A multicenter randomized, controlled trial. Nutrition. 2009;25(11-12):1129-36.
40. Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Health-related quality of life in WHO class II-III obese men losing weight with very-low-energy diet and behaviour modification: a randomised clinical trial. Int J Obes Relat Metab Disord. 2002;26(4):487-95.
41. Arai K, Miura J, Ohno M, Yokoyama J, Ikeda Y. Comparison of clinical usefulness of very-low-calorie diet and supplemental low-calorie diet. American Journal of Clinical Nutrition. 1992;56(1 Suppl):275S-6S.
42. Foster GD, Wadden TA, Feurer ID, et al. Controlled trial of the metabolic effects of a very-low-calorie diet: short- and long-term effects. American Journal of Clinical Nutrition. 1990;51(2):167-72.
43. Foster GD, Wadden TA, Peterson FJ, Letizia KA, Bartlett SJ, Conill AM. A controlled comparison of three very-low-calorie diets: effects on weight, body composition, and symptoms. American Journal of Clinical Nutrition. 1992;55(4):811-7.
44. Inoue S, Okamura A, Okamoto M, Tanaka K, Sugimasa T, Takamura Y. Effects of very low calorie diet (VLCD) on body weight, blood glucose and serum lipid metabolism in severe obesity with glucose intolerance. International Journal of Obesity. 1989;13 Suppl 2:183-4.
45. Toubro S, Astrup A. Randomised Comparison of Diets for Maintaining Obese Subjects' Weight after Major Weight Loss: Ad Lib, Low FAt, High Carbohydrate Diet v Fixed Energy Intake. BMJ. 1997;314(7073):29-34.
46. Simonen P, Gylling H, Howard AN, Miettinen TA. Introducing a new component of the metabolic syndrome: low cholesterol absorption. American Journal of Clinical Nutrition. 2000;72(1):82-8.
47. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. International Journal of Obesity. 1989;13 Suppl 2:39-46.
48. Rolland C. Weight loss in obese women with Polycystic Ovary Syndrome (PCOS) (ISRCTN01915371). 2011.
49. Bliddal H, Leeds AR, Stigsgaard L, Astrup A, Christensen R. Weight loss as treatment for knee osteoarthritis symptoms in obese patients: 1-year results from a randomised controlled trial. Ann Rheum Dis. 2011;70:1798-803.
50. Pekkarinen T, Mustajoki P. Comparison of behavior therapy with and without very-low-energy diet in the treatment of morbid obesity. A 5-year outcome. Arch Intern Med. 1997;157(14):1581-5.
51. Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(12):954-62.
52. Rolland C, Hession M, Murray S, Wise A, Broom I. Randomized clinical trial of standard dietary treatment versus a low-carbohydrate/high-protein diet or the LighterLife Programme in the management of obesity .[Erratum appears in J Diabetes. 2011 Dec;3(4):356]. J Diabetes. 2009;1(3):207-17.
53. Rolland C, Broom J. A randomised controlled trial of a low-carbohydrate vs. a very low calorie diet - A two year follow up. Obesity Reviews. 2010;11:245-6.
54. Rossner S, Flaten H. VLCD versus LCD in long-term treatment of obesity. Int J Obes Relat Metab Disord. 1997;21(1):22-6.
55. Ryttig KR, Flaten H, Rossner S. Long-term effects of a very low calorie diet (Nutrilett) in obesity treatment. A prospective, randomized, comparison between VLCD and a hypocaloric diet+behavior modification and their combination. Int J Obes Relat Metab Disord. 1997;21(7):574-9.

56. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: Randomised controlled study. British Medical Journal. 2000;320(7238):827-32.
57. Torgerson JS, Lissner L, Lindroos AK, Kruijer H, Sjostrom L. VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial. International Journal of Obesity. 1997;21(11):987-94.
58. Lantz H, Peltonen M, Agren L, Torgerson JS. A dietary and behavioural programme for the treatment of obesity. A 4-year clinical trial and a long-term posttreatment follow-up. J Intern Med. 2003;254(3):272-9.
59. Tuomilehto HP, Seppa JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. American journal of respiratory and critical care medicine. 2009;179(4):320-7.
60. Tuomilehto H, Gylling H, Peltonen M, et al. Sustained improvement in mild obstructive sleep apnea after a diet- and physical activity-based lifestyle intervention: postinterventional follow-up. The American journal of clinical nutrition. 2010;92(4):688-96.
61. Wadden TA, Stunkard AJ. Controlled trial of very low calorie diet, behavior therapy, and their combination in the treatment of obesity. Journal of Consulting and Clinical Psychology. 1986;54(4):482-8.
62. Wadden TA, Stunkard AJ, Liebschutz J. Three-year follow-up of the treatment of obesity by very low calorie diet, behavior therapy, and their combination. Journal of Consulting and Clinical Psychology. 1988;56(6):925-8.
63. Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: Comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. Journal of Consulting and Clinical Psychology. 1994;62(1):165-71.
64. Wing RR, Marcus MD, Salata R, Epstein LH, Miaskiewicz S, Blair EH. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med. 1991;151(7):1334-40.
65. Wing RR, Shiffman S, Drapkin RG, Grilo CM, McDermott M. Moderate versus restrictive diets: Implications for relapse. Behavior Therapy. 1995;26(1):5-24.
66. Wing RR, Anglin K. Effectiveness of a behavioral weight control program for blacks and whites with NIDDM. Diabetes Care. 1996;19(5):409-13.
67. Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: Does including an intermittent very-low-calorie diet improve outcome? Am J Med. 1994;97(4):354-62.